| Similar Articles |
|---|
 |
The Motley Fool
June 20, 2007
Brian Lawler |
GPC Markets Itself GPC showcases itself at two investor conferences last week. The biotech's shares have nearly doubled off of its 52-week lows, following the announcement of successful phase 3 results and anticipation of FDA approval for its lead compound.   |
The Motley Fool
November 1, 2007
Brian Lawler |
Achtung, GPC! The German biotech sector took a hit yesterday, after GPC Biotech and partner Pharmion announced that GPC's lead drug, satraplatin, had failed an important endpoint in phase 3 testing. |
The Motley Fool
March 31, 2008
Brian Lawler |
GPC Recaps a Tough Year Development-stage drugmaker GPC Biotech releases its year-end financial results after a 2007 in which the FDA depth-charged its lead drug. |
The Motley Fool
September 26, 2006
Brian Lawler |
GPC's Trial Glee A new platinum-based cancer treatment yields encouraging results. Investors, take note. |
The Motley Fool
May 16, 2007
Brian Lawler |
GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note. |
BusinessWeek
October 16, 2006
Gene G. Marcial |
Spectrum Has A Rosy Glow When Spectrum Pharmaceuticals announced on Sept. 25 that results from the Phase 3 trials of its Satraplatin were "positive," its shares bolted. |
The Motley Fool
August 10, 2007
Brian Lawler |
GPC Picking Up the Pieces GPC Biotech announced second-quarter financial results last week, in the shadow of a setback; they are awaiting more data on a crucial drug candidate. |
The Motley Fool
July 25, 2007
Brian Lawler |
GPC Must Wait An advisory panel recommends against approving GPC's lead drug right now. Investors, take note. |
The Motley Fool
June 27, 2007
Brian Lawler |
Waiting on GPC Exciting development-stage drugmaker GPC's marketing partner files a European marketing application for its top drug. |
The Motley Fool
July 31, 2007
Brian Orelli |
GPC Takes a Pit Stop The biotech company pulls its New Drug Application for Satraplatin. There is something twisted about having to wait to get a drug to market because it's performing better than expected. Investors, take note. |
The Motley Fool
July 23, 2007
Brian Lawler |
GPC's Date With the FDA A document released by the FDA outlines its concerns with GPC's lead drug. Investors, take note. |
BusinessWeek
November 3, 2003 |
Spectrum's New Cancer Weapons Several big investors have been buying little-known Spectrum Pharmaceuticals, which develops anticancer agents that have previous clinical data to back their efficacy and safety. |
BusinessWeek
July 25, 2005
Gene G. Marcial |
Spectrum's Cancer Drugs Could be Winners Biotechs got battered earlier this year, but some investors are optimistic about Spectrum Pharmaceuticals because of the anticancer agents it has in advanced clinical trials. |
The Motley Fool
September 28, 2006
Brian Lawler |
Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens. |
The Motley Fool
February 28, 2006
Rich Smith |
1,001 Teutonic Nights, Part 5 Investors, get to know Germany: GPC Biotech... Deutsche Telekom... Siemens... SAP... |
The Motley Fool
March 8, 2007
Selena Maranjian |
Collect Underwear and Retire Rich If Phase 1 is save money for retirement, and phase 3 is retire, then there's a very important Phase 2: Invest intelligently. One shortcut is to simply invest in a broad-market index fund that also charges a bargain-basement expense ratio. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
